Swedish maker of laboratory equipment and culture media used in IVF and fertility clinics worldwide.
Swedish maker of laboratory equipment and culture media used in IVF and fertility clinics worldwide.
Culture media that clinics buy anew for every IVF cycle is a recurring line, so volumes follow treatment cycles, while incubators and imaging systems are capital purchases that lead to media sales. Genetic testing services were added by buying Igenomix.
In one line: A niche fertility-technology leader like a smaller CooperSurgical.
Moat: narrow (installed base, customer qualification, brand). Leading global position in IVF consumables/equipment with embedded clinic workflows, though competition exists from larger medtech.
Headquarters: Gothenburg, Sweden · Founded: 1994 · Employees: 1,151
Size Vitrolife (VITR.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $1.57B, the 100th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 117.70 on 18 Nov 2026.
Performance Over six months the shares gained 12.7%, against -2.3% for the median peer and +2.8% for the Sweden market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 1.9% over the last twelve months (peer median +8.6%); the operating margin is 19.2% (peer median 8.2%).
Valuation It trades at 27.0× forward earnings against a peer median of 22.0× (7th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 22% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -0 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.7 points below its cost of capital (11.6% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 3.44B | SEK 3.44B | SEK 3.61B | SEK 3.51B | SEK 3.23B |
| Revenue growth | — | -5% | +3% | +9% | — |
| Gross profit | SEK 1.80B | SEK 1.75B | SEK 1.88B | SEK 1.74B | SEK 1.55B |
| EBITDA | SEK 1.07B | SEK 1.04B | SEK 1.24B | SEK 1.16B | SEK 1.04B |
| Net income | -SEK 4.96B | -SEK 5.01B | SEK 513M | -SEK 3.85B | SEK 394M |
| Free cash flow | SEK 603M | SEK 460M | SEK 815M | SEK 689M | SEK 585M |
| Capital expenditure | SEK 93.0M | SEK 247M | SEK 202M | SEK 120M | SEK 87.0M |
| Total debt | SEK 1.73B | SEK 1.60B | SEK 2.09B | SEK 2.09B | SEK 2.23B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Vitrolife VITR.ST | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% |
| Cooper Companies (The) COO | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% |
| Merck KGaA MRK.DE | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VITR.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +20.4% | -1.1% | 4th highest of 21 |
| 6-month return | +12.7% | -2.3% | 6th highest of 21 |
| Distance from 52-week high | -22.8% | -26.7% | 9th highest of 21 |
| Revenue growth (TTM) | -1.9% | +8.6% | lowest of 21 |
| Operating margin | 19.2% | 8.2% | 6th highest of 21 |
| Forward P/E | 27.0× | 22.0× | 7th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 22.2% | 11.2% | 3rd most demanding of 16 |
| Growth delivered (Del g) | +22.5% | +12.7% | 4th highest of 16 |
| Hurdle (Req g minus delivered) | -0.3 pp | -6.8 pp | 8th most demanding of 16 |
| ROIC minus cost of capital | -5.7 pp | +2.3 pp | 7th lowest of 21 |
| EV / EBITDA | 15.7× | 11.8× | 5th most expensive of 11 |
| Net debt / EBITDA | 0.8× | -1.1× | 6th most indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vitrolife VITR.ST | Sweden | $1.57B | +13% | -2% | 19% | 27.0× | 22.2% | +22.5% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |
| Wuxi Unicomp Technology 688531.SS | China | $1.58B | -49% | +53% | 12% | 35.8× | n/a | n/a |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Cofoe Medical Technology 301087.SZ | China | $1.60B | -6% | +33% | 10% | 25.1× | 11.2% | +7.4% |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |